Taro Pharmaceutical Industries Ltd. Provides Results For September 30, 2015
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and six months ended September 30, 2015.
Quarter ended September 30, 2015 Highlights - compared to September 30, 2014
Net sales of $212.1 million, decreased $38.8 million, or 15.5%. This net sales decline is principally due to the impact of net charges taken to meet contractual obligations associated with price adjustments and the changing U.S. market dynamics on certain products. On a pro-forma basis, adjusted for the price protection provision, net sales would have decreased 7.7%
Help employers find you! Check out all the jobs and post your resume.
Quarter ended September 30, 2015 Highlights - compared to September 30, 2014
Net sales of $212.1 million, decreased $38.8 million, or 15.5%. This net sales decline is principally due to the impact of net charges taken to meet contractual obligations associated with price adjustments and the changing U.S. market dynamics on certain products. On a pro-forma basis, adjusted for the price protection provision, net sales would have decreased 7.7%
Help employers find you! Check out all the jobs and post your resume.